ASCO-Biophatech

ASCO-Biophatech is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, dedicated to the discovery and development of next-generation immune cell therapies. The company's primary focus is on addressing unmet medical needs in solid tumors through its proprietary CAR-T and TCR-T technology platforms. Its lead candidate, ASCO-01, is a CAR-T therapy targeting Claudin 18.2 for the treatment of gastric and pancreatic cancers. Additionally, the company is advancing ASCO-02, a TCR-T therapy targeting NY-ESO-1 for synovial sarcoma and other solid malignancies. ASCO-Biophatech aims to improve the safety and therapeutic window of cell therapies by optimizing cell persistence and tumor infiltration.